Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to April 2020 in the Republic of Bashkortostan, and amon...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c0cfd0526a68496b9746ee7f2af922a5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c0cfd0526a68496b9746ee7f2af922a52021-11-30T16:55:01ZTreatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review1815-14341815-144210.26442/18151434.2021.1.200785https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a52021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70477/51397https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to April 2020 in the Republic of Bashkortostan, and among them, 68.47% had stage IV cancer. International professional guidelines suggest screening for early HCC detection. Systemic drug therapy is the treatment of choice for inoperable HCC according to professional guidelines. Inhibition of the VEGF pathway is one of the current methods of therapy for advanced HCC. Lenvatinib is a tyrosine kinase inhibitor for the treatment of advanced HCC that is not subject to local interventions. This article provides a description of a clinical case of successful treatment of a 67-year-old patient with advanced hepatocellular carcinoma. He was appointed for targeted therapy with lenvatinib for HCC that was not subject to local interventions, which led to long-term stabilization. There was a positive trend in the patients condition from the first weeks of therapy. The working capacity was restored. The therapy showed a satisfactory tolerability profile.Konstantin V. MenshikovAleksandr V. SultanbaevKamila T. AkhmetgareevaDanila O. LipatovIP Habib O.N.articlehepatocellular cancertargeted therapylenvatinibefficacytoleranceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 156-161 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
hepatocellular cancer targeted therapy lenvatinib efficacy tolerance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
hepatocellular cancer targeted therapy lenvatinib efficacy tolerance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Konstantin V. Menshikov Aleksandr V. Sultanbaev Kamila T. Akhmetgareeva Danila O. Lipatov Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
| description |
Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to April 2020 in the Republic of Bashkortostan, and among them, 68.47% had stage IV cancer. International professional guidelines suggest screening for early HCC detection. Systemic drug therapy is the treatment of choice for inoperable HCC according to professional guidelines. Inhibition of the VEGF pathway is one of the current methods of therapy for advanced HCC. Lenvatinib is a tyrosine kinase inhibitor for the treatment of advanced HCC that is not subject to local interventions. This article provides a description of a clinical case of successful treatment of a 67-year-old patient with advanced hepatocellular carcinoma. He was appointed for targeted therapy with lenvatinib for HCC that was not subject to local interventions, which led to long-term stabilization. There was a positive trend in the patients condition from the first weeks of therapy. The working capacity was restored. The therapy showed a satisfactory tolerability profile. |
| format |
article |
| author |
Konstantin V. Menshikov Aleksandr V. Sultanbaev Kamila T. Akhmetgareeva Danila O. Lipatov |
| author_facet |
Konstantin V. Menshikov Aleksandr V. Sultanbaev Kamila T. Akhmetgareeva Danila O. Lipatov |
| author_sort |
Konstantin V. Menshikov |
| title |
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
| title_short |
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
| title_full |
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
| title_fullStr |
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
| title_full_unstemmed |
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
| title_sort |
treatment of metastatic hepatocellular carcinoma with lenvatinib. case report and literature review |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5 |
| work_keys_str_mv |
AT konstantinvmenshikov treatmentofmetastatichepatocellularcarcinomawithlenvatinibcasereportandliteraturereview AT aleksandrvsultanbaev treatmentofmetastatichepatocellularcarcinomawithlenvatinibcasereportandliteraturereview AT kamilatakhmetgareeva treatmentofmetastatichepatocellularcarcinomawithlenvatinibcasereportandliteraturereview AT danilaolipatov treatmentofmetastatichepatocellularcarcinomawithlenvatinibcasereportandliteraturereview |
| _version_ |
1718406469557157888 |